RS62901B1 - Jedinjenja sa antitumorskom aktivnošću - Google Patents

Jedinjenja sa antitumorskom aktivnošću

Info

Publication number
RS62901B1
RS62901B1 RS20220136A RSP20220136A RS62901B1 RS 62901 B1 RS62901 B1 RS 62901B1 RS 20220136 A RS20220136 A RS 20220136A RS P20220136 A RSP20220136 A RS P20220136A RS 62901 B1 RS62901 B1 RS 62901B1
Authority
RS
Serbia
Prior art keywords
phenyl
ethoxymethyl
methyl
oxazol
amine
Prior art date
Application number
RS20220136A
Other languages
English (en)
Serbian (sr)
Inventor
Alain Moussy
Abdellah Benjahad
Didier Pez
Franck Sandrinelli
Jason Martin
Willy Picoul
Emmanuel Chevenier
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of RS62901B1 publication Critical patent/RS62901B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20220136A 2015-02-05 2016-02-05 Jedinjenja sa antitumorskom aktivnošću RS62901B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15154028.3A EP3053920B1 (en) 2015-02-05 2015-02-05 Compounds with anti-tumoral activity
PCT/EP2016/052523 WO2016124747A1 (en) 2015-02-05 2016-02-05 Compounds with anti-tumoral activity
EP16703138.4A EP3253749B1 (en) 2015-02-05 2016-02-05 Compounds with anti-tumoral activity

Publications (1)

Publication Number Publication Date
RS62901B1 true RS62901B1 (sr) 2022-03-31

Family

ID=52450012

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220136A RS62901B1 (sr) 2015-02-05 2016-02-05 Jedinjenja sa antitumorskom aktivnošću

Country Status (24)

Country Link
US (1) US10570122B2 (enExample)
EP (2) EP3053920B1 (enExample)
JP (1) JP6713000B2 (enExample)
KR (1) KR102544132B1 (enExample)
CN (1) CN107531685B (enExample)
AR (1) AR103629A1 (enExample)
AU (1) AU2016214283B2 (enExample)
BR (1) BR112017016883B1 (enExample)
CA (1) CA2975644C (enExample)
CY (1) CY1124948T1 (enExample)
DK (1) DK3253749T3 (enExample)
ES (2) ES2796276T3 (enExample)
HR (1) HRP20220114T1 (enExample)
HU (1) HUE059063T2 (enExample)
IL (1) IL253779A0 (enExample)
LT (1) LT3253749T (enExample)
MX (1) MX377742B (enExample)
PL (1) PL3253749T3 (enExample)
PT (1) PT3253749T (enExample)
RS (1) RS62901B1 (enExample)
RU (1) RU2758259C2 (enExample)
TW (1) TWI748938B (enExample)
WO (1) WO2016124747A1 (enExample)
ZA (1) ZA201705537B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CN109467531A (zh) * 2017-09-08 2019-03-15 沈阳科创化学品有限公司 一种取代吡啶二羧酸衍生物的制备方法
CN112225733B (zh) * 2020-11-25 2022-12-09 湖南科技大学 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用
US12502854B2 (en) 2022-09-27 2025-12-23 Illinois Tool Works Inc. Tire repair system
AU2024225818A1 (en) * 2023-02-24 2025-09-11 Ab Science Compounds for treating myeloid diseases with chromosomal abnormalities
CN117720459A (zh) * 2023-12-26 2024-03-19 江苏希迪制药有限公司 一种阿贝西利中间体5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺制备工艺

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US810665A (en) * 1905-10-10 1906-01-23 Joseph Mlada Mold for butter.
US1346834A (en) * 1918-08-17 1920-07-20 Charles E Mcmanus Resilient rod
US3740420A (en) 1967-11-28 1973-06-19 Crown Zellerbach Corp Pharmaceutical compositions with dimethyl sulfoxide
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
CA1163561A (en) 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4411893A (en) 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
CA1236029A (en) 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
US4615699A (en) 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6448272B1 (en) * 1998-12-07 2002-09-10 Smithkline Beecham Corporation Myt1 kinase inhibitors
JP4216947B2 (ja) * 1999-05-18 2009-01-28 三井化学株式会社 アミン化合物
MXPA05001277A (es) * 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
ATE465731T1 (de) * 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
CA2578122A1 (en) * 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
AU2006244203B2 (en) * 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
JP5214096B2 (ja) * 2005-06-17 2013-06-19 富士フイルムファインケミカルズ株式会社 新規なビピリジン誘導体
EP1904065A2 (en) * 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
AU2006290814B2 (en) * 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
PT2402319T (pt) * 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
FR2901273B1 (fr) * 2006-05-19 2010-12-24 Anaconda Pharma Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
BRPI0806811A2 (pt) * 2007-01-23 2011-09-13 Palau Pharma Sa derivados de purina
KR20090113382A (ko) * 2007-02-22 2009-10-30 아이알엠 엘엘씨 Ｇ 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
EP2310384B1 (en) * 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
JP2012180281A (ja) * 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
WO2011006903A1 (en) * 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
EP2499282B1 (en) * 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
CN102812022B (zh) * 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
GB201012105D0 (en) * 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
EP2616443A1 (en) * 2010-09-14 2013-07-24 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
WO2012068210A1 (en) * 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012162461A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012166463A2 (en) * 2011-05-27 2012-12-06 Neosome Life Sciences, LLC Aminooxazole inhibitors of cyclin dependent kinases
ES2573831T3 (es) * 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
KR101896035B1 (ko) * 2011-08-23 2018-09-07 덕산네오룩스 주식회사 유기전기소자용 신규 화합물, 이를 이용하는 유기전기소자 및 그 단말
CN103436048B (zh) * 2013-08-08 2014-12-03 陕西师范大学 硫脲供体双桥链有机染料及其应用
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
MX2016012460A (es) * 2014-03-24 2017-05-04 Ab Science Derivados de oxazol sustituidos por diazaespiroalcanona como inhibidores de torosina quinasa de bazo.
EP3144307A1 (en) * 2015-09-18 2017-03-22 AB Science Novel oxazole derivatives that inhibit syk

Also Published As

Publication number Publication date
TWI748938B (zh) 2021-12-11
PT3253749T (pt) 2022-02-03
PL3253749T3 (pl) 2022-03-07
JP2018504415A (ja) 2018-02-15
HRP20220114T1 (hr) 2022-04-15
CN107531685A (zh) 2018-01-02
LT3253749T (lt) 2022-02-25
RU2017127484A3 (enExample) 2019-08-14
DK3253749T3 (da) 2022-02-28
ES2905412T3 (es) 2022-04-08
CA2975644A1 (en) 2016-08-11
US10570122B2 (en) 2020-02-25
CN107531685B (zh) 2021-04-23
EP3053920A1 (en) 2016-08-10
EP3253749B1 (en) 2021-12-08
MX2017010157A (es) 2017-12-18
WO2016124747A1 (en) 2016-08-11
AU2016214283B2 (en) 2020-07-16
US20180079747A1 (en) 2018-03-22
CY1124948T1 (el) 2023-01-05
IL253779A0 (en) 2017-09-28
MX377742B (es) 2025-03-11
ES2796276T3 (es) 2020-11-26
KR102544132B1 (ko) 2023-06-15
BR112017016883A2 (pt) 2018-03-27
AR103629A1 (es) 2017-05-24
HUE059063T2 (hu) 2022-10-28
KR20170117407A (ko) 2017-10-23
TW201636345A (zh) 2016-10-16
EP3053920B1 (en) 2020-04-08
ZA201705537B (en) 2020-11-25
RU2017127484A (ru) 2019-03-05
JP6713000B2 (ja) 2020-06-24
EP3253749A1 (en) 2017-12-13
BR112017016883B1 (pt) 2023-03-07
AU2016214283A1 (en) 2017-08-10
HK1243700A1 (zh) 2018-07-20
CA2975644C (en) 2025-05-06
RU2758259C2 (ru) 2021-10-27

Similar Documents

Publication Publication Date Title
JP7390415B2 (ja) ニューロキニン－１受容体アンタゴニストとしての化合物およびその使用
CA2975644C (en) COMPOUNDS WITH ANTI-TUMOR ACTIVITY
JP5944503B2 (ja) 選択的プロテインキナーゼ阻害剤
CA2973773C (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
BR112014010563B1 (pt) compostos inibidores da aminopirimidina quinase
JP2018504415A5 (enExample)
WO2013016720A2 (en) Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
WO2016055479A1 (en) Tetrahydroisoquinoline derivatives
KR20250048008A (ko) 헤테로사이클 rbm39 조절제
EP3350176B1 (en) Novel oxazole derivatives that inhibit syk
ES3049795T3 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
US20180202388A1 (en) Piston for an internal combustion engine and method for producing the piston for an internal combustion engine
CA3231660A1 (en) Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
JP2008542382A (ja) 癌および他の疾患の処置用プロテインキナーゼ阻害剤としての置換ビアリール複素環誘導体
EP3122744B1 (en) Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors
HK1225031A1 (en) Compounds with anti-tumoral activity
HK1225031A (en) Compounds with anti-tumoral activity
HK1243700B (en) Compounds with anti-tumoral activity
EA053341B1 (ru) Гетероциклические модуляторы rbm39